174 related articles for article (PubMed ID: 38398014)
1. Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study.
Domański P; Piętak M; Kruczyk B; Jarosińska J; Mydlak A; Demkow T; Darewicz M; Sikora-Kupis B; Dumnicka P; Kamzol W; Kucharz J
Biomedicines; 2024 Feb; 12(2):. PubMed ID: 38398014
[TBL] [Abstract][Full Text] [Related]
2. Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study.
Domański P; Jarosińska J; Kruczyk B; Piętak M; Mydlak A; Demkow T; Kuncman Ł; Darewicz M; Sikora-Kupis B; Dumnicka P; Kucharz J
Contemp Oncol (Pozn); 2023; 27(3):190-197. PubMed ID: 38239858
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
[No Abstract] [Full Text] [Related]
4. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
5. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Tomida R; Takahashi M; Matsushita Y; Kojima T; Yamana K; Kandori S; Bando Y; Nishiyama N; Yamashita S; Taniguchi H; Monji K; Ishiyama R; Tatarano S; Masui K; Matsuda A; Kaneko T; Motoshima T; Shiraishi Y; Kira S; Murashima T; Hara H; Matsumura M; Kitamura H; Miyake H; Furukawa J;
Clin Genitourin Cancer; 2024 Jun; 22(3):102094. PubMed ID: 38714434
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
Sato R; Matsushita Y; Takemura A; Sugiyama M; Watanabe K; Watanabe H; Tamura K; Motoyama D; Nagata M; Otsuka A; Furuse H; Miyake H
Anticancer Res; 2024 Feb; 44(2):781-786. PubMed ID: 38307571
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Santoni M; Heng DY; Bracarda S; Procopio G; Milella M; Porta C; Matrana MR; Cartenì G; Crabb SJ; De Giorgi U; Basso U; Masini C; Calabrò F; Vitale MG; Santini D; Massari F; Galli L; Fornarini G; Ricotta R; Buti S; Zucali P; Caffo O; Morelli F; Carrozza F; Martignetti A; Gelibter A; Iacovelli R; Mosca A; Atzori F; Vau N; Incorvaia L; Ortega C; Scarpelli M; Lopez-Beltran A; Cheng L; Paolucci V; Graham J; Pierce E; Scagliarini S; Sepe P; Verzoni E; Merler S; Rizzo M; Sorgentoni G; Conti A; Piva F; Cimadamore A; Montironi R; Battelli N
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905816
[TBL] [Abstract][Full Text] [Related]
10. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
[TBL] [Abstract][Full Text] [Related]
11. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
12. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
13. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G; Lazzarin A; Santoni M; Trentini F; Giorgi U; Brighi N; Tommasi C; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; Silini EM; Rescigno P; Rebuzzi SE; Fornarini G; Quaini F; Giudice GC; Banna GL; Buti S
Front Biosci (Elite Ed); 2023 Jul; 15(3):20. PubMed ID: 37743233
[TBL] [Abstract][Full Text] [Related]
14. Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.
Gerendash BS; Creel PA
Onco Targets Ther; 2017; 10():5053-5064. PubMed ID: 29089775
[TBL] [Abstract][Full Text] [Related]
15. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
16. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Schmidinger M; Motzer RJ; Rolland F; Staehler M; Rink M; Retz M; Csoszi T; McCaffrey JA; De Giorgi U; Caserta C; Duran I; Benzaghou F; Clary DO; Albiges L; Choueiri TK; Tannir NM
Acta Oncol; 2022 Jan; 61(1):52-57. PubMed ID: 34736367
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Osanto S; van der Hulle T
Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors.
Poon DM; Chan K; Leung AK; Ng B; Cheung FY; Siu SW;
Drugs Context; 2023; 12():. PubMed ID: 37378080
[TBL] [Abstract][Full Text] [Related]
20. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
